Treatment effect of remdesivir on the mortality of hospitalised COVID-19 patients in Switzerland across different patient groups: a tree-based model analysis

Article Immunology

Remdesivir Plus Dexamethasone Versus Dexamethasone Alone for the Treatment of Coronavirus Disease 2019 (COVID-19) Patients Requiring Supplemental O2 Therapy: A Prospective Controlled Nonrandomized Study

Aldo Marrone et al.

Summary: Treatment with remdesevir plus dexamethasone in COVID-19 patients requiring supplemental O(2) therapy showed significant reduction in mortality, shorter hospital stay, and faster viral clearance.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19

Marco Falcone et al.

Summary: This prospective observational study evaluated the relationship between early use of remdesivir and disease progression in patients with COVID-19 pneumonia. The study found that early use of remdesivir can reduce disease progression in patients with mild to moderate COVID-19. In addition, a history of dyspnea at home was independently associated with progression to severe COVID-19.

CLINICAL THERAPEUTICS (2022)

添加到收藏夹

Review Urology & Nephrology

COVID-19 and chronic kidney disease: an updated overview of reviews

Sara S. Jdiaa et al.

Summary: This review focuses on the impact of Chronic Kidney Disease (CKD) on the poor outcomes of COVID-19 and highlights the importance of identifying strategies to prevent COVID-19 infection among patients with CKD.

JOURNAL OF NEPHROLOGY (2022)

添加到收藏夹

Article Immunology

Optimal Timing of Remdesivir Initiation in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Administered With Dexamethasone

Carlos K. H. Wong et al.

Summary: Initiation of remdesivir prior to or simultaneously with dexamethasone was associated with significantly shorter time to clinical improvement and positive IgG antibody, lower risk of in-hospital death, in addition to shorter length of hospital stay in patients with moderate COVID-19.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Review Medicine, General & Internal

Major Update 2: Remdesivir for Adults With COVID-19: A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points

Anjum S. Kaka et al.

Summary: This review updates the evidence on the use of Remdesivir for adult patients with COVID-19. The findings suggest that Remdesivir may not significantly reduce mortality but increases the proportion of recovered patients. It may reduce time to clinical improvement and decrease serious adverse events, but may increase any adverse events.

ANNALS OF INTERNAL MEDICINE (2022)

添加到收藏夹

Review Infectious Diseases

Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19

Tomas Cihlar et al.

Summary: Remdesivir, the first antiviral for COVID-19, has been widely used to treat 10 million patients worldwide. Its development path started more than a decade earlier in the search for a cure for hepatitis C virus. This journey represents an important example of pandemic preparedness, supported by John C. Martin's sustained commitment.

ANTIVIRAL THERAPY (2022)

添加到收藏夹

Review Microbiology

Efficacy of early use of remdesivir: a systematic review of subgroup analysis

Manuel David Gil-Sierra et al.

Summary: This study systematically interprets subgroup analyses on the early use of remdesivir, and finds that in severe COVID-19 cases, early use of remdesivir provides greater benefits in terms of time to clinical improvement and clinical status score for patients with symptom onset of less than 7 days.

REVISTA ESPANOLA DE QUIMIOTERAPIA (2022)

添加到收藏夹

Article Critical Care Medicine

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase atrial

Thomas L. Holland et al.

Summary: This study compared the efficacy of tixagevimab-cilgavimab with placebo in hospitalized COVID-19 patients receiving remdesivir and standard care. The results showed that tixagevimab-cilgavimab did not improve sustained recovery, but it was safe and associated with lower mortality.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

Summary: This study presents the final results of the Solidarity trial and meta-analyses of mortality in relevant trials. The findings suggest that remdesivir does not have a significant effect on COVID-19 patients who are already on ventilators. However, it does have a small effect against death or progression to ventilation in other hospitalized patients.

LANCET (2022)

添加到收藏夹

Review Immunology

COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology

Hyun Jee Han et al.

Summary: COVID-19 is associated with cancer, with cancer patients showing worsened symptoms and higher mortality when infected. Vaccines offer a promising solution to reduce the impact of the virus on cancer patients.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Review Infectious Diseases

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Jennifer A. Belsky et al.

Summary: Severe COVID-19 caused by SARS-CoV-2 has a greater impact on immunocompromised patients such as cancer and solid organ transplant recipients, leading to higher comorbidities and poorer hospital outcomes. However, hematopoietic cell transplant recipients and pediatric cancer patients tend to have clinical presentations and outcomes similar to the general population.

JOURNAL OF INFECTION (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study

Hawra Ali Hussain Alsayed et al.

Summary: This retrospective cohort study explored the impact of timing of remdesivir initiation on clinical outcomes in hospitalized COVID-19 patients. Early administration of remdesivir within 7 days of symptom onset was associated with reduced need for mechanical ventilation and lower mortality at 28 days.

PLOS ONE (2021)

添加到收藏夹

Review Medicine, General & Internal

Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies

Yahya Mahamat-Saleh et al.

Summary: This study found that diabetes, hypertension, obesity, and smoking were associated with higher COVID-19 mortality, contributing to nearly 30% of COVID-19 deaths.

BMJ OPEN (2021)

添加到收藏夹

Article Respiratory System

Predictors of mortality in patients with severe COVID-19 pneumonia - a retrospective study

M. Mahendra et al.

Summary: This study investigated mortality predictors in severe COVID-19 pneumonia patients admitted to ICU in India. Factors such as SpO(2)/FiO(2) ratio, age, duration of symptoms, serum ferritin levels, respiratory rate, comorbidities, and the use of remdesivir were found to be associated with increased mortality. Early consideration of remdesivir may help prevent excess mortality related to COVID-19.

ADVANCES IN RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Cohort profile: SARS-CoV-2/COVID-19 hospitalised patients in Switzerland

Thiabaud Amaury et al.

Summary: The SARS-CoV-2/COVID-19 pandemic emerged in China in late 2019 and quickly spread globally, affecting millions of people. Switzerland was heavily impacted, leading to the establishment of a surveillance database in February 2020 in cooperation with the Federal Office of Public Health. The database included 3645 hospitalized patients, providing valuable data on the epidemiology, risk factors, and clinical course of COVID-19 cases in the country.

SWISS MEDICAL WEEKLY (2021)

添加到收藏夹

Review Anesthesiology